Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 774

Sort by

Sort Order Select

Journal Articles

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani

Blood (2021) 138 (9): 749–757.

https://doi.org/10.1182/blood.2021010764

Published: 2021

Journal Articles

Introduction to a review series on platelets and cancer

José A. López

Blood (2021) 137 (23): 3151–3152.

https://doi.org/10.1182/blood.2020010237

Published: 2021

Journal Articles

Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor

Ken Morita, MD PhD, Shuning He, PhD, Radosław P. Nowak, PhD, Jinhua Wang, PhD, Nathanael Gray, PhD, Eric S. Fischer, PhD, A. Thomas Look, MD

Blood (2019) 134 (Supplement_1): 406.

https://doi.org/10.1182/blood-2019-123573

Published: 2019

Journal Articles

Class I PI3K Is Required for HSC Differentiation

Kristina Ames, PhD, Imit Kaur, PhD, Meng Tong, Shayda Hemmati, PhD, Ellen Tein, Shira Glushakow-Smith, Lindsay Gurska, Kira Gritsman, MD PhD

Blood (2019) 134 (Supplement_1): 2461.

https://doi.org/10.1182/blood-2019-123823

Published: 2019

Journal Articles

CDK6 Antagonizes TP53-Induced Responses during Tumorigenesis

Veronika Sexl, MD PhD, Karoline Kollmann, PhD, Florian Bellutti

Blood (2019) 134 (Supplement_1): SCI-15.

https://doi.org/10.1182/blood-2019-121101

Published: 2019

Journal Articles

Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Gary H. Lyman, MD MPH, Kathryn Richert-Boe, MD MPH, Lois Lamerato, PhD, Manpreet Kaur, MPH, MBA, Neel Shah, BPharm, PhD, Tatiana Lawrence, MD, Devi Sundaresan, MS, Amanda Silvia, BS, Ahuva Hanau, BS, Derek Weycker, PhD

Blood (2019) 134 (Supplement_1): 5854.

https://doi.org/10.1182/blood-2019-123524

Published: 2019

Journal Articles

Implementation of a Cardio Oncology Protocol in Uruguay

Pía Oldan, MD, Andreina Gomez, MD, Gabriel Parma, MD, Cecilia Guillermo, MD, Lilián Díaz, MD, Matilde Boada, MD MSc

Blood (2019) 134 (Supplement_1): 5888.

https://doi.org/10.1182/blood-2019-127068

Published: 2019

Journal Articles

Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors

Kendall H Sullivan, PharmD, Michael Toscani, PharmD, Tayla Poretta, PharmD, Ciera Patzke, PharmD, BCOP, Thushara Korattyil, PharmD, Denalee O'Malley, PhD MSW, Victor Gonzalez, MA, MS, Joseph Barone, PharmD, Andrew M. Evens, DO,MSc

Blood (2019) 134 (Supplement_1): 2134.

https://doi.org/10.1182/blood-2019-123459

Published: 2019

Journal Articles

Predictive Value of Cellular Blood Indices for All-Cause Mortality in Acute Pulmonary Embolism

Brett Slajus, Yevgeniy Brailovsky, DO, Trung Phan, Iman Darwish, Jawed Fareed, PhD, Amir Darki, MD MSc

Blood (2019) 134 (Supplement_1): 2103.

https://doi.org/10.1182/blood-2019-127425

Published: 2019

Journal Articles

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Yu Qian, PhD, Henry W.B. Johnson, PhD, Christopher J. Kirk, PhD, Eric Lowe, BS, Dustin McMinn, PhD, Beatriz Millare, BS, Tony Muchamuel, MS, Jinhai Wang, PhD

Blood (2019) 134 (Supplement_1): 2076.

https://doi.org/10.1182/blood-2019-125988

Published: 2019

Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl

Blood (2019) 134 (Supplement_1): 3939.

https://doi.org/10.1182/blood-2019-125153

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

N. Nora Bennani, MD, Grzegorz Nowakowski, MD, Lisa M. Rimsza, MD, Alex A Adjei, MD PhD, Laurence Doyle, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 4090.

https://doi.org/10.1182/blood-2019-129104

Published: 2019

Journal Articles

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Vinita Dhir, BSc, Lara Zibdawi, Harminder K Paul, MSc, Osvaldo Espin-Garcia, PhD, Christine I Chen, MD, Michael Crump, MD FRCPC, Robert Kridel, MDMPH,PhD, Vishal Kukreti, MD, John Kuruvilla, MD, Donna E Reece, MD, Rodger E Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Anca Prica, MD

Blood (2019) 134 (Supplement_1): 62.

https://doi.org/10.1182/blood-2019-131281

Published: 2019

Journal Articles

Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma

Kim De Veirman, Siyang Yan, Ken Maes, Nathan De Beule, MD, Sylvia Faict, MSc, Elke De Bruyne, PhD, Eline Menu, PhD, Karin Vanderkerken, PhD

Blood (2019) 134 (Supplement_1): 4335.

https://doi.org/10.1182/blood-2019-126834

Published: 2019

Journal Articles

Rspo-LGR4 Cooperates with HOXA9 to Sustain Self-Renewal in Acute Myeloid Leukemia

Nunki Hassan, Basit Salik, Alastair Duly, PhD, Jenny Yingzi Wang, PhD

Blood (2019) 134 (Supplement_1): 2669.

https://doi.org/10.1182/blood-2019-129704

Published: 2019

Journal Articles

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD MMSc, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 2868.

https://doi.org/10.1182/blood-2019-127566

Published: 2019

Journal Articles

Cachexia at Diagnosis adversely predicts outcomes in patients with Aggressive B-Cell NHL receiving standard of care treatment: A Prospective Observational Study from India

Vivek S Radhakrishnan, MDDM,MSc, Reena Nair, MD, Anwesha Patra, Saurabh Jayant Bhave, MD, Jeevan Kumar Garg, MDDNB, Mohandas Mallath, MDDNB

Blood (2019) 134 (Supplement_1): 2907.

https://doi.org/10.1182/blood-2019-126295

Published: 2019

Journal Articles

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Inge Oudaert, MSc, Sylvia Faict, MSc, Ludovic D'Auria, PhD, Jonas Dehairs, PhD, Ken Maes, Philip Vlummens, MD, Lotte Jacobs, BSc, Kim De Veirman, Elke De Bruyne, PhD, Karel Fostier, MD, Isabelle Vande Broek, MD PhD, Rik Schots, Karin Vanderkerken, PhD, Johannes V. Swinnen, PhD, Eline Menu, PhD

Blood (2019) 134 (Supplement_1): 3058.

https://doi.org/10.1182/blood-2019-122857

Published: 2019

Journal Articles

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy

Alice Di Rocco, Arianna Di Rocco, MD, Alessio Farcomeni, PhD, Luigi Petrucci, MD, Giulia De Luca, MD, Federico Mazzon, MD, Maurizio Martelli, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 2888.

https://doi.org/10.1182/blood-2019-131417

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Introduction to a review series on platelets and cancer

Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor

Class I PI3K Is Required for HSC Differentiation

CDK6 Antagonizes TP53-Induced Responses during Tumorigenesis

Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Implementation of a Cardio Oncology Protocol in Uruguay

Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors

Predictive Value of Cellular Blood Indices for All-Cause Mortality in Acute Pulmonary Embolism

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

Quality of Life and Caregiver Burden in Patients and Their Caregivers Undergoing Outpatient Autologous Stem Cell Transplantation Compared to Inpatient Transplantation

Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma

Rspo-LGR4 Cooperates with HOXA9 to Sustain Self-Renewal in Acute Myeloid Leukemia

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Cachexia at Diagnosis adversely predicts outcomes in patients with Aggressive B-Cell NHL receiving standard of care treatment: A Prospective Observational Study from India

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only